Search  in | Advanced
   Print  
FOR IMMEDIATE RELEASE
November 22, 2004
CONTACT:
Jennifer Garfinkel
+1.301.215.6526
publicrelations@aabb.org

AABB Praises FDAs Work on Final
Good Tissue Practice Rule

Measure designed to improve human cell and tissue
safety through broader regulation

BETHESDA, MD AABB commends the U.S. Food and Drug Administrations (FDA) efforts to enhance industry safety with its issuance of the final rule on current good tissue practice (CGTP). The new regulations, entitled Current Good Tissue Practice for Human Cell, Tissue, and Cellular and Tissue-Based Establishments, require a broad range of human cells, tissues, and cellular and tissue-based products (HCT/Ps) to be manufactured in compliance with GTP standards.

We are pleased that the AABB Standards were one of several organizational standards reviewed in preparation for determining the provisions of this regulation, said Karen Shoos Lipton, CEO of AABB. AABB supports the rule and is pleased that the regulations set out general objectives rather than requiring specific procedures. AABB strives to be certain that its Standards are compatible with regulations and that all of the minimum FDA requirements are included.

AABB has been setting voluntary standards for hematopoietic progenitor cells since 1991. AABB began incorporating a quality management system along with the rigorous technical requirements into all of its standard setting activities in 1997. This concept of quality and technical requirements is consistent with the practices described in the CGTP. AABBs institutional members have been at the forefront of meeting quality management systems and technical requirements in blood banking, including setting standards for hematopoietic stem cells. It has accredited more than 110 hematopietic progenitor cells services and 26 cord blood services.

AABB

Established in 1947, AABB (formerly known as the American Association of Blood Banks) is an international, not-for-profit association dedicated to the advancement of science and the practice of transfusion medicine and related biological therapies. The association is committed to improving health by developing and delivering standards, accreditation and educational programs and services that optimize patient and donor care and safety. AABB membership consists of approximately 1,800 institutions and 8,000 individuals, including physicians, scientists, administrators, medical technologists, nurses, researchers, blood donor recruiters and public relations personnel. Members are located in all 50 states and 80 countries.

Last modified on 4/12/2006 4:53:37 PM
What's New!
AABB Weekly Report - December 19, 2008
Details
AABB Patient and Donor Safety Center Named a Patient Safety Organization by Department of Health and Human Services
Details
The Proposed 4th edition of Standards for Perioperative Autologous Blood Collection and Administration
Details
The Proposed 26th edition of Standards for Blood Banks and Transfusion Services
Details
CMS Publishes 2009 Hospital Outpatient Prospective Payment System Rule
Details
FDA Liaison Meeting Summary
Details
2007 National Blood Collection and Utilization Survey
Details
Call for AABB Award Nominations
Details
Association Bulletin #08-04 - Strategies to Reduce Adverse Reactions and Injuries in Younger Donors
Details
First Ever National Biovigilance Network in the U.S. Reaches $1 Million in Funding, Prepares for Fall Pilot Launch
Details
List of AABB-Accredited Facilities with Approved Variances for ISBT 128
Details